Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical results published Aug ...
Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...
At a median follow-up of 13.2 years, dose-escalated hypofractionated intensity-modulated radiation therapy led to fewer treatment failures in men with localized, intermediate-risk prostate cancer than ...
LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...
BUFFALO, N.Y. – Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback